This Annual Report covers accomplishments and activities from March 1, 2022 to June 30, 2023.
Dear Colleagues,
We are pleased to present our 2022-2023 Annual Report. Through projects, NIIMBL-led Programs, and talent initiatives, our community continues to seize opportunities to drive innovations that will enhance patient access to medicines...
In September 2022, President Biden signed Executive Order (E.O.) 14081 on Advancing Biotechnology and Biomanufacturing Innovation for a Sustainable, Safe, and Secure American Bioeconomy. The E.O. directs the United States Government to expand training and education opportunities for all Americans in biotechnology and biomanufacturing. Specifically...
Advances in biotechnology over the past decade have led to an explosion of innovative new products that touch many aspects of American life, from novel RNA vaccines and cell-based medicines, to engineered meats and plants, to fuels and chemicals made from renewable resources, and much more. Science and engineering continue to unveil new ways of...
The National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) issues Innovation of the Biopharmaceutical Manufacturing Talent Pipeline, a whitepaper addressing the innovation needs and concerns fueling the employment gap in the biopharmaceutical manufacturing industry. The whitepaper proposes solutions that will directly assist...
This Annual Report covers NIIMBL’s accomplishments from March 1, 2021 to February 28, 2022.
The NIIMBL mission is to accelerate biopharmaceutical manufacturing innovation, support the development of standards that enable more efficient and rapid manufacturing capabilities, and educate and train a world-leading biopharmaceutical manufacturing...
NIIMBL, the Manufacturing USA institute for biopharmaceutical manufacturing innovation, has released its 2020–2021 Annual Report covering the period from March 2020 through February 2021. Amid the global COVID-19 pandemic, NIIMBL swiftly backed innovative projects that supported the U.S. response to the COVID-19 pandemic. Its community came...
The National Institute of Standards and Technology (NIST) Office of Advanced Manufacturing (OAM) has published a report outlining the evaluation and renewal process for NIST-sponsored Manufacturing USA institutes. The report describes the performance standards developed by NIST following Manufacturing USA’s 2019 reauthorization, which allows NIST...
We are pleased to share NIIMBL’s 2019-2020 Annual Report covering the period from March 2019 through February 2020. It celebrates their collective accomplishments, which reflect the commitment and engagement of diverse individuals and organizations across the biopharmaceutical manufacturing ecosystem.
As they share and reflect on NIIMBL’s many...
Cyberbiosecurity is an emerging discipline that addresses the unique vulnerabilities and threats that occur at the intersection of cyberspace and biotechnology. Advances in technology and manufacturing are increasing the relevance of cyberbiosecurity to the biopharmaceutical manufacturing community in the United States. Threats may be associated...
The biopharmaceutical industry makes a substantial impact on the health, well-being, and economic prosperity of the nation. The industry develops and manufactures life-changing therapies for patients and contributes significantly to the U.S. economy. Currently, the industry accounts for nearly $800B of total economic activity per year and directly...
